|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:activities
|
CD K4/6 inhibitor
|
|
gptkbp:brand
|
gptkb:abemaciclib
|
|
gptkbp:can_be_used_with
|
gptkb:letrozole
gptkb:tamoxifen
|
|
gptkbp:clinical_trial
|
gptkb:MONARCH_1
gptkb:MONARCH_2
gptkb:MONARCH_3
gptkb:hormone_receptor-positive_breast_cancer
Phase III
metastatic breast cancer
adjuvant treatment
|
|
gptkbp:contraindication
|
hypersensitivity
liver impairment
severe neutropenia
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:effective_date
|
February 2017
|
|
gptkbp:has_ability
|
100 mg
50 mg
200 mg
150 mg
|
|
gptkbp:healthcare
|
gptkb:battle
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Verzenio
|
|
gptkbp:ingredients
|
gptkb:abemaciclib
|
|
gptkbp:invention
|
2027
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:name
|
gptkb:battle
|
|
gptkbp:pharmacokinetics
|
highly protein-bound
half-life of approximately 18 hours
metabolized by CY P3 A4
|
|
gptkbp:population
|
adult men
adult women
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:price
|
approximately $10,000 per month
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
neutropenia
|
|
gptkbp:symbolism
|
gptkb:battle
|
|
gptkbp:targets
|
CD K4/6
|